EirGenix Inc. Capacity Update February 2024: Large Molecule

EirGenix is Taiwan's largest CDMO for mammalian and microbial-derived, clinical, and commercial manufacturing of biologics (mAbs, bi-specifics, ADC, vaccines, and pDNA). EirGenix is inspected and approved by the USFDA, Japan PMDA, Australia TGA, and the EU EMA. EirGenix has immediate availability of capacity up to 12 x 2,000 L SUBs for mammalian cells and up to 150 L scale for microbial and that will increase to 350L and 1,000L by end of this year.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Outsourced Pharma